Edaravone - Generic Drug Details

» See Plans and Pricing

« Back to Dashboard

What are the generic drug sources for edaravone and what is the scope of patent protection?

Edaravone is the generic ingredient in one branded drug marketed by Mitsubishi Tanabe and is included in one NDA. There is one patent protecting this compound. Additional information is available in the individual branded drug profile pages.

Edaravone has seven patent family members in six countries.

One supplier is listed for this compound.

Summary for edaravone

International Patents:	7
US Patents:	1
Tradenames:	1
Applicants:	1
NDAs:	1
Suppliers / Packagers:	1
Bulk Api Vendors:	131
Clinical Trials:	28
Patent Applications:	1,726
Formulation / Manufacturing:	see details
DailyMed Link:	edaravone at DailyMed

Recent Clinical Trials for edaravone

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Terra Biological LLC	Phase 1
Clinical Research in ALS and Related Disorders for Therapeutic Development	Phase 1
Omar Jawdat	Phase 1

See all edaravone clinical trials

Synonyms for edaravone

(MCI-186)
1-Fenyl-3-methyl-2-pyrazolin-5-on
1-Fenyl-3-methyl-2-pyrazolin-5-on [Czech]
1-PEHNYL-3-METHYL-5-PYRAZALONE
1-Phenyl-3-methyl-2-pyrazolin-5-on
1-Phenyl-3-methyl-5-oxo-2-pyrazoline
1-Phenyl-3-methyl-5-pyrazolone
1-Phenyl-3-methylpyrazolone
1-Phenyl-3-methylpyrazolone-5
2 4-Dihydro-5-methyl-2-phenyl-3H-pyrazol-3-one
2-Pyrazolin-5-one, 3-methyl-1-phenyl-
2,4-dihydro-2-phenyl-5-methyl-3H-pyrazol-3-one
2,4-Dihydro-5-methyl-2-phenyl-3H-pyrazol-3-one
3-Methyl-1-phenyl-1H-pyrazol-5(4H)-one
3-METHYL-1-PHENYL-2-PYRAZOLIN-5-ONE
3-METHYL-1-PHENYL-2-PYRAZOLIN-5-ONE (MCI-186)
3-Methyl-1-phenyl-2-pyrazolin-5-one, 99%
3-methyl-1-phenyl-2-pyrazolin-5one
3-Methyl-1-phenyl-2-pyrazoline-5-one
3-Methyl-1-phenyl-2-pyrazoline-5-one, 99%
3-Methyl-1-phenyl-2-pyrazoline-5-one, purum, >=98.0% (NT)
3-Methyl-1-phenyl-2-pyrazoline-5-one, SAJ special grade
3-methyl-1-phenyl-4,5-dihydro-1H-pyrazol-5-one
3-Methyl-1-phenylpyrazol-5-one
3H-Pyrazol-3-one, 2,4-dihydro-5-methyl-2-phenyl-
3H-Pyrazol-3-one,4-dihydro-5-methyl-2-phenyl-
4CA-0486
4E-901
5-methyl-2-phenyl-2,4-dihydro-3-pyrazolone
5-Methyl-2-phenyl-2,4-dihydro-3H-pyrazol-3-one
5-Methyl-2-phenyl-2,4-dihydro-3H-pyrazol-3-one (Edaravone)
5-Methyl-2-phenyl-2,4-dihydro-3H-pyrazol-3-one #
5-methyl-2-phenyl-2,4-dihydro-pyrazol-3-one
5-methyl-2-phenyl-2,4-dihydropyrazol-3-one
5-Pyrazolone, 3-methyl-1-phenyl-
89-25-8
AB00375776_14
AB00375776_15
AB2000046
AC-4745
ACT07289
AE-641/00371017
AI3-03557
AK128848
AKOS000313817
AM20060748
Antipyrine related compound a
Antipyrine Related Compound A, United States Pharmacopeia (USP) Reference Standard
BBL011741
BCBcMAP01_000127
BCP26336
BCP9000635
BCPP000246
BDBM50200541
Bio1_000438
Bio1_000927
Bio1_001416
Bio2_000448
Bio2_000928
BRD-K35458079-001-04-2
BRD-K35458079-001-12-5
BRD-K35458079-001-23-2
BRN 0609575
BSPBio_001235
BSPBio_002601
C.I. Developer 1
C13008
CAS-89-25-8
CCG-39352
CCRIS 512
CDS1_000986
CHEBI:31530
CHEMBL290916
CI Developer 1
CS-1832
CTK3E8611
D01552
DB-002517
DB12243
Developer Z
DivK1c_001018
DivK1c_002026
DSSTox_CID_1130
DSSTox_GSID_21130
DSSTox_RID_75961
DTXSID9021130
EC 201-891-0
Edaravone (MCI-186)
Edaravone (USAN/JP17/INN)
Edaravone [USAN:INN]
EINECS 201-891-0
F0391-0021
FT-0608243
HMS1362M17
HMS1792M17
HMS1990M17
HMS2234M19
HMS3266F04
HMS3403M17
HMS3411L05
HMS3654L15
HMS3675L05
HMS503K17
HMS557M18
HSDB 4102
HY-B0099
IDI1_001018
IDI1_002203
InChI=1/C10H10N2O/c1-8-7-10(13)12(11-8)9-5-3-2-4-6-9/h2-6H,7H2,1H
KBio1_001018
KBio2_000575
KBio2_000747
KBio2_003143
KBio2_003315
KBio2_005711
KBio2_005883
KBio3_001029
KBio3_001030
KBio3_001821
KBioGR_000575
KBioGR_001502
KBioSS_000575
KBioSS_000747
KS-00000X6I
KSC448M1D
LS-1892
M0687
Maybridge1_005738
MCI-186
MCI-186, Radicut, 89-25-8
Methylphenylpyrazolone
MFCD00003138
MLS000069602
MLS001146878
MLS002415675
MLS006011753
Monopyrazolone
NCGC00018218-01
NCGC00018218-02
NCGC00018218-03
NCGC00018218-04
NCGC00018218-05
NCGC00018218-06
NCGC00018218-07
NCGC00018218-08
NCGC00018218-10
NCGC00018218-17
NCGC00022665-02
NCGC00022665-04
NCGC00022665-05
NCGC00022665-06
NCGC00164015-01
NCGC00256515-01
NCGC00259296-01
NCI-C03952
NE10266
NINDS_001018
Norantipyrine
Norphenazone
NSC 12
NSC-26139
NSC-2629
NSC-758622
NSC26139
NSC2629
NSC758622
Opera_ID_1057
Pharmakon1600-01503635
Phenazone impurity A, European Pharmacopoeia (EP) Reference Standard
Phenyl methyl pyrazolone
Phenylmethylpyrazolone
PubChem13301
Q-200386
Q335099
QELUYTUMUWHWMC-UHFFFAOYSA-N
Radicava
Radicava (TN)
Radicut
Radicut (TN)
Radicut;MCI-186
RTR-028045
s1326
SB19128
SBI-0051836.P002
SC-13582
SCHEMBL4704
SMR000059020
SPBio_001508
Spectrum_000267
SPECTRUM1503635
Spectrum2_001574
Spectrum3_000971
Spectrum4_001091
Spectrum5_001217
SR-01000000135
SR-01000000135-2
SR-01000000135-3
SR-01000000135-5
ST012744
ST2410773
STK201315
SW148216-2
Tocris-0786
Tox21_112077
Tox21_112077_1
Tox21_201747
Tox21_302819
TR-028045
WLN: T5NMV DHJ BR& E1
Z50145861
ZINC18203737

US Patents and Regulatory Information for edaravone

+ Get email alerts for changes to this table

Glossary

Subscribe to access the full database, or Start Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Mitsubishi Tanabe	RADICAVA	edaravone	SOLUTION;INTRAVENOUS	209176-001	May 5, 2017		RX	Yes	Yes	Start Trial	Start Trial				Start Trial
Mitsubishi Tanabe	RADICAVA	edaravone	SOLUTION;INTRAVENOUS	209176-001	May 5, 2017		RX	Yes	Yes	Start Trial	Start Trial				Start Trial
Mitsubishi Tanabe	RADICAVA	edaravone	SOLUTION;INTRAVENOUS	209176-002	Nov 15, 2018		RX	Yes	Yes	Start Trial	Start Trial				Start Trial
Mitsubishi Tanabe	RADICAVA	edaravone	SOLUTION;INTRAVENOUS	209176-001	May 5, 2017		RX	Yes	Yes	Start Trial	Start Trial				Start Trial
Mitsubishi Tanabe	RADICAVA	edaravone	SOLUTION;INTRAVENOUS	209176-002	Nov 15, 2018		RX	Yes	Yes	Start Trial	Start Trial				Start Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Exclusivity Expiration

International Patents for edaravone

Subscribe to access the full database, or Start Trial
Country	Patent Number	Estimated Expiration
Japan	WO2002034264	Start Trial
Spain	2248144	Start Trial
Germany	60022560	Start Trial
Japan	3758164	Start Trial
Austria	303808	Start Trial
European Patent Office	1405637	Start Trial
World Intellectual Property Organization (WIPO)	0234264	Start Trial
>Country	>Patent Number	>Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

By using our website you are consenting to our use of cookies in accordance with our privacy policy.